AOD-9604 Protocol: Complete Cycling & Dosing Guide

Overview

AOD-9604 is a synthetic peptide fragment (amino acids 176-191) derived from human growth hormone, engineered to deliver fat-loss benefits without the metabolic complications of full-length hGH. Unlike complete GH therapy, AOD-9604 does not significantly elevate IGF-1 levels or induce insulin resistance—a critical distinction for long-term tolerability.

The compound works by activating beta-3 adrenergic receptors in adipose tissue, triggering lipolysis (fat breakdown) while simultaneously inhibiting lipogenesis (fat storage). It also shows mechanistic promise for joint health through cartilage-protective pathways, though human clinical data in this domain remain limited.

AOD-9604 is available in three administration routes: subcutaneous/intramuscular injection, oral, and intranasal. Injectable delivery provides the most predictable pharmacokinetics and remains the standard for research and clinical investigation. The compound carries a favorable short-term safety profile, with no significant glucose dysregulation or insulin sensitivity impairment at therapeutic doses—a major advantage over full GH replacement.

Critical note: AOD-9604 is not FDA-approved and is classified as a research chemical. Long-term human safety data beyond 24 weeks are limited. All use is investigational.

Standard Protocol

Injectable Protocol (Primary Route)

Recommended Starting Dose: 250 mcg once daily via subcutaneous injection

Dosing Range: 250–300 mcg daily (some users extend to 350 mcg, though data supporting efficacy above 300 mcg are limited)

Administration Frequency: Once daily, preferably in the morning or evening with consistent timing

Typical Cycle Length: 8–12 weeks on, 4–8 weeks off

Reconstitution (if powder):

• Use bacteriostatic water (not standard saline) at a ratio of 1 mL per 10 mg of powder
• Example: 10 mg vial + 1 mL bacteriostatic water = 100 mcg per 0.1 mL (10 units on an insulin syringe)
• Mix gently—do not shake aggressively
• Allow 5–10 minutes for full dissolution before drawing

Storage:

• Powder: room temperature or refrigerated (2–8°C) until reconstitution; stable for 12+ months
• Reconstituted: refrigerate at 2–8°C; stable for 2–3 weeks if using bacteriostatic water
• Never freeze once reconstituted

Injection Sites: Rotate between subcutaneous sites (abdomen, thigh, upper arm) to minimize localized irritation. A 25–29 gauge insulin syringe is standard.

Oral Protocol

Recommended Starting Dose: 500 mcg once daily

Dosing Range: 500–1,000 mcg daily

Timing: Take with or without food (food may slightly reduce absorption)

Typical Cycle Length: 8–12 weeks on, 4–6 weeks off

Note on Bioavailability: Oral AOD-9604 has lower and more variable absorption than injectable routes. Efficacy data for oral dosing remain limited. Most clinical research employed injectable administration.

Intranasal Protocol

Recommended Starting Dose: 250–300 mcg once daily (equivalent to injectable dose)

Typical Cycle Length: 8–12 weeks on, 4–6 weeks off

Administration: Spray into one nostril once daily; alternate nostrils on alternate days to prevent mucosal irritation

Note on Efficacy: Intranasal bioavailability is less established than injection. This route offers convenience but sacrifices predictability.

Goal-Specific Protocols

Fat Loss Protocol (Primary Indication)

Objective: Accelerate subcutaneous and visceral fat reduction while minimizing muscle loss

Dose: 250–300 mcg daily via injection

Cycle Structure: 10–12 weeks on, 4 weeks off

Stacking Recommendation: Combines effectively with caloric deficit (500–750 kcal/day below maintenance) and moderate-intensity steady-state cardio (20–30 min, 5 days/week)

Expected Fat Loss Timeline:

• Weeks 1–3: Minimal visible change; metabolic adaptation phase
• Weeks 4–8: Noticeable fat reduction, particularly in abdominal and hip regions
• Weeks 8–12: Continued loss with possible plateauing as deficit duration increases

Adjustment Strategy: If fat loss stalls after week 8, extend the cycle to 14 weeks rather than increasing dose. Increasing dose above 300 mcg provides diminishing returns.

Joint Health & Cartilage Support Protocol

Objective: Support cartilage regeneration and reduce osteoarthritis progression (intra-articular focus)

Dose: 250 mcg daily via injection (systemic) + consider localized intra-articular injection (0.25 mg per site) if administered by medical professional

Cycle Structure: 12 weeks on, 6 weeks off (longer cycle to support tissue remodeling)

Stacking Recommendation: Combine with hyaluronic acid oral supplement (500–1,500 mg daily) and Type II collagen peptides (5–10 g daily)

Expected Timeline:

• Weeks 1–4: Baseline; minimal subjective change
• Weeks 5–8: Possible reduction in morning stiffness; improved range of motion
• Weeks 9–12: More consistent joint comfort; reduced lameness in weight-bearing activities

Note: Efficacy data for systemic AOD-9604 on human joints are absent. Animal studies show promise but translation to humans is not yet proven.

Metabolic Optimization Protocol (General Body Composition)

Objective: Improve fat-to-muscle ratio without aggressive dieting or muscle loss

Dose: 250 mcg daily via injection

Cycle Structure: 10 weeks on, 6 weeks off

Stacking Recommendation: Pair with resistance training 4 days/week and adequate protein intake (0.8–1.0 g per pound of body weight)

Expected Timeline:

• Weeks 1–3: Adaptation; possible mild fatigue
• Weeks 4–7: Visible fat loss with preserved or slight muscle gain if training is consistent
• Weeks 8–10: Plateau phase; consider cycle end and recovery

How to Administer Step-by-Step

Subcutaneous Injection (Injectable)

Materials Needed:

• Reconstituted AOD-9604 vial
• 25–29 gauge insulin syringe (0.5–1 mL)
• Alcohol prep pad
• Sterile cotton ball

Procedure:

1. Prepare the Injection Site: Choose a subcutaneous site (upper abdomen, thigh, or outer arm). Rotate sites daily to prevent lipohypertrophy or atrophy.

2. Clean the Vial: Wipe the rubber septum of the reconstituted AOD-9604 vial with an alcohol pad. Allow to dry.

3. Draw the Dose: With the syringe, draw back the plunger to the appropriate unit marking (e.g., 0.025 mL for a 250 mcg dose if reconstituted at 10,000 mcg/mL). Insert the needle into the vial at a slight angle and withdraw the dose. Ensure no air bubbles remain in the syringe.

4. Prepare the Injection Site: Swab the skin with an alcohol pad using a circular motion. Allow 10–15 seconds for drying.

5. Inject: Pinch the skin gently to create a fold. Insert the needle at a 45–90° angle into the subcutaneous tissue. Push the plunger steadily and withdraw the needle.

6. Apply Pressure: Use a sterile cotton ball to apply light pressure for 5–10 seconds.

7. Document: Note the injection site and time for rotation purposes.

Oral Administration

1. Measure or dispense the prescribed dose (typically a capsule or pre-measured powder).
2. Consume with or without food.
3. Maintain consistent timing (ideally the same time daily).

Intranasal Administration

1. Gently blow nose to clear nasal passages.
2. Tilt head slightly and insert the nasal applicator into one nostril.
3. Spray once; do not sniff forcefully.
4. Repeat on alternate nostril on the following day.

Cycle Example: 10-Week Fat Loss Protocol

Expected Outcomes (approximate):

• Fat loss: 8–15 lbs over 10 weeks (dependent on diet adherence and baseline body composition)
• Energy: Stable to improved by week 4
• Recovery: 2–3 weeks post-cycle before re-dosing

What to Expect: Timeline of Effects

Days 1–3

• Possible mild injection-site redness or swelling (resolves within 24 hours)
• Transient headache in first 1–2 hours post-injection (common; diminishes with continued use)
• Mild fatigue or lethargy (usually fades by day 3)

Days 4–14

• Metabolic activation; appetite may stabilize or increase slightly
• Energy stabilizes; many users report improved training capacity
• Fat loss becomes measurable if combined with caloric deficit

Weeks 3–4

• Consistent fat loss visible, particularly in face, abdomen, and thighs
• Muscle preservation improved if adequate protein intake maintained
• Injection site reactions (if occurring) typically resolve

Weeks 5–8

• Peak fat loss window; most noticeable body composition change
• Energy remains high; training performance stable
• Possible mild plateauing of fat loss by week 8 (normal)

Weeks 9–12

• Fat loss continues but at a slower rate
• Cycle fatigue may emerge; consider end-of-cycle protocols
• Recovery compounds (rest, increased intake) beneficial at this point

Common Protocol Mistakes

1. Exceeding 300 mcg Daily

Doses above 300 mcg show no evidence of proportional efficacy gains. Higher doses increase side-effect burden without additional fat-loss benefit. Respect the ceiling dose.

2. Cycling Without Adequate Off-Time

Using AOD-9604 continuously without 4–8 week breaks risks desensitization and metabolic adaptation. Off-cycles are essential for maintaining responsiveness. Structure: 8–12 weeks on, 4–8 weeks off.

3. Poor Injection Technique

Rotating injection sites prevents lipohypertrophy (fat lumps) and localized irritation. Injecting into scar tissue or the same spot repeatedly reduces bioavailability and increases inflammation.

4. Ignoring Reconstitution Stability

Reconstituted AOD-9604 degrades if frozen or stored improperly. Use bacteriostatic water (not saline) and refrigerate. Discard after 3 weeks if reconstitution occurs before use.

5. Neglecting Diet and Training

AOD-9604 is a fat-loss accelerator, not a standalone solution. Without a caloric deficit and resistance training, results are minimal. The compound magnifies the effects of a solid protocol—it does not replace one.

6. Mixing Routes Without Planning

Do not alternate between oral, injectable, and intranasal dosing within the same cycle. Each route has different absorption kinetics. Pick one and maintain consistency.

7. Expecting Muscle Growth

AOD-9604 is not a muscle-building agent. Its mechanism focuses on lipolysis. Muscle gain during a cycle results from adequate protein, resistance training, and preserved caloric surplus—not from the peptide itself.

How to Stack with Other Compounds

Stack 1: AOD-9604 + Caloric Deficit (Optimal Fat Loss)

• AOD-9604: 250–300 mcg daily (injection)
• Diet: 500–750 kcal deficit from maintenance
• Cardio: 20–30 min moderate-intensity, 5 days/week
• Duration: 10–12 weeks

Rationale: Maximizes fat loss while preserving muscle. AOD-9604 enhances lipolysis; caloric deficit forces fat mobilization.

Stack 2: AOD-9604 + Collagen Peptides + Hyaluronic Acid (Joint Support)

• AOD-9604: 250 mcg daily (injection)
• Collagen Peptides (Type II): 5–10 g daily
• Hyaluronic Acid: 500–1,500 mg daily
• Duration: 12 weeks on, 6 weeks off

Rationale: Synergistic cartilage support. AOD-9604 stimulates chondrogenesis; collagen provides substrate; hyaluronic acid enhances joint lubrication.

Stack 3: AOD-9604 + Testosterone (if applicable, medical supervision required)

• AOD-9604: 250–300 mcg daily (injection)
• Testosterone: Clinical replacement dose (75–100 mg weekly if deficient)
• Caloric Baseline: Slight surplus or maintenance
• Duration: 12 weeks

Rationale: Testosterone preserves muscle during fat loss; AOD-9604 accelerates fat mobilization. Combined approach yields improved body composition without catabolic loss.

Stack 4: AOD-9604 + BPC-157 (Recovery Enhancement)

• AOD-9604: 250 mcg daily (injection)
• BPC-157: 250 mcg daily (injection)
• Duration: 8–10 weeks

Rationale: AOD-9604 targets fat loss; BPC-157 supports tissue repair and recovery. Useful for users with concurrent injury or joint issues.

Compounds to Avoid Stacking

• Full-Length hGH: Redundant mechanisms; risk of compounded side effects (joint pain, carpal tunnel, hyperglycemia)
• Insulin Secretagogues (e.g., GLP-1 agonists at high doses): AOD-9604 does not affect glucose; combining agents with insulin effects may increase hypoglycemia risk
• High-Dose Corticosteroids: Counteract fat-loss effects; may increase infection risk at injection sites

Protocol Quick Reference Table

Signs AOD-9604 Is Working

• Visible fat loss in target areas (abdomen, hips, thighs) by weeks 4–6
• Improved mirror aesthetics without significant strength loss in resistance training
• Reduced waist circumference (measure weekly)
• Energy increase and improved training capacity by week 2–3
• Stable or rising muscle definition if protein intake is adequate (not strength gains, but definition)

When to Adjust Protocol

If fat loss plateaus by week 8:

• Extend the cycle to 14 weeks rather than increasing dose
• Slightly decrease caloric intake (additional 100–150 kcal deficit) only if already at 500 kcal below maintenance
• Increase training frequency or intensity
• Do not exceed 300 mcg daily

If side effects emerge:

• Reduce dose to 200 mcg